RCC is a common malignancy with an incidence that has risen over the last 30 years largely due to incidental findings on imaging. During this time, the evaluation and management of RCC has evolved due to a greater understanding of the genetics of the disease, changes in the TNM staging system, and a trend to less invasive and organ-sparing surgical treatments. Minimally invasive procedures will continue to be at the forefront of treatment in the decades to come. With the advent of biologic response modifiers, additional therapies are now available for patients with metastatic RCC. Nurses and physicians caring for patients with RCC must be knowledgeable about these newer treatment modalities, which patients are appropriate candidates for such therapies, anticipated response rates, and the management of potential adverse effects. A multidisciplinary approach, which includes nurses and allied personnel, will continue to be vital in the management of these patients.
Objectives and CNE Evaluation Form appear on page 191.
Urologic Nursing Editorial Board Statements of Disclosure
In accordance with ANCC-COA governing rules Urologic Nursing Editorial Board statements of disclosure are published with each CNE offering. The statements of disclosure for this offering are published below.
Susanne A. Quallich, ANP-BC, NP-C, CUNP, disclosed that she is on the Consultants'
Bureau for Coloplast.
All other Urologic Nursing Editorial Board members reported no actual or potential conflict of interest in relation to this continuing nursing education activity.
Urol Nurs. 2012;32(4):182-190. © 2012 Society of Urologic Nurses and Associates